ALBUQUERQUE, N.M., Oct. 15 /PRNewswire-FirstCall/ -- Two clinical research scientists this month joined Biomoda, Inc. (http://www.biomoda.com) of Albuquerque, NM, to assist with commercialization efforts of the company’s early lung cancer detection testing and other cancer diagnostic technology.
“Constance Dorian brings strong analytical skills and significant understanding of diagnostic products development and FDA regulations to Biomoda. She will be an important asset in all our clinical studies,” said John Cousins, President of Biomoda. “I’m equally pleased to have Brett Roden on our team. He is highly skilled in research and production science with a solid background in pharmacological and biomolecular engineering.”
Before joining Biomoda, Ms. Dorian worked as a research scientist in clinical studies of fluorescence spectroscopy to noninvasively measure diabetes. She managed Technical Operations for several California biomedical firms that manufactured diagnostic products and commercial controls for the clinical and hospital laboratory markets, developed and tested in vitro diagnostic products and developed new drugs in the treatment of thrombosis. Mr. Roden formerly worked as a research assistant in the clinical studies of multiple assays, including in vivo microdialysis, cell isolation, tissue preparation, radioligand binding assays and protein quantification.
Biomoda’s technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope. The patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.
Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.
Contact: John Cousins (505) 821-0875
CONTACT: John Cousins of Biomoda, Inc., +1-505-821-0875
Web site: http://www.biomoda.com/
